chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient was fine after sitting for 15 minutes in the vaccination room. Upon standing up the patient had sudden dizziness and lightheadedness to which I had the patient sit down in the chair for an additional 10-15 minutes. The patient's pulse, and blood pressure seemed ok, didn't have any symptoms of low blood sugar as he is a diabetic. He was given cold water to which he drank about half a water bottle. The patient stated they were ready to get up and go home to which he had the same dizziness and unsteadiness on his feet and walked an additional 5-10 steps to which this reaction still occurred so I had the patient sit down for another additional 10-15 minutes. He had more water and then he was escorted to a cab to go home to which he had similar dizziness but that it was better than how he felt earlier. I told patient to notify me at the pharmacy when he was home and safe. HIs primary care doctor was notified of the situation to which they stated they would follow up with the patient as well.
Flu-like symptoms; Fever; Chills; Body Aches; This case was reported by a other health professional via call center representative and described the occurrence of influenza-like symptoms in unspecified number of patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix at an unknown dose. On an unknown date, unknown after receiving Shingrix, the patient experienced influenza-like symptoms, fever, chills and general body pain. On an unknown date, the outcome of the influenza-like symptoms, fever, chills and general body pain were unknown.   It was unknown if the reporter considered the influenza-like symptoms, fever, chills and general body pain to be related to Shingrix.  Additional details were reported as follows: The Chief Administrative Officer stated that they were hesitant in administering Shingrix to patient's in the sense that the side effects from the vaccine could be confused with symptoms of COVID-19. The reporter stated that the they administered hundreds of doses of Shingrix and patients have experienced normal or expected side effects, such as flu like symptoms which includes fever, chills, and body aches. No other information was reported. The reporter consented to follow up.
Fever. Injection site inflammation. Injection site erythema. Injection site swelling. From initial information received on 08/Jan/2004 from a health care professional regarding an adverse event occurring in the USA, it was reported that a three year old male patient received his second dose of DAPTACEL (lot number C1624AA and expiration date 25/Apr/2006) administered in the right deltoid (route of administration not reported), a second dose of IPOL (lot number X0372 and expiration date 14/Jan/2006) administered in the left deltoid (route of administration not reported) and his second dose of MMR (lot number 0271N and expiration date of 07/mar/2005), manufacturer Merck, administered subcutaneously in the right arm on 06/Jan/2004 at 10:00 AM. The following day,the child developed a large erythematous area around the injection site (specific site not reported), as well as upper arm swelling and fever. The reaction was described as possibly being cellulitis, but it was not stated if this was diagnosed. The patient was seen by a physician. The patient's recovery status was not reported. The reporting facility of this case is the same reporting facility of case 2004-00090.
This spontaneous report as received from a nurse refers to an unspecified number of patient of unknown demographics. No concurrent conditions or medical history were provided. On an unknown date, those patients were vaccinated with doses of ZOSTAVAX injection (strength, dose, route of administration, indication, lot # and expiry date unspecified), that were improperly stored. No concomitant medications were reported. No adverse effects were reported. Additional information has been requested.
One month post vax the pt experienced fever, swelling hands, dizziness and double vision. These adverse events continued one year later. Engerix B was discontinued. As of 08/01/2000 the outcome of the event is ongoing.
Patient received Dose 1 two years ago; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 81-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (first dose received approximately two years ago).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: Reporter was a pharmacy technician. Age at vaccination was not applicable to this report Pharmacist reported that, patient received their first dose of Shingrix approximately two years ago Second dose not yet administered, which led to incomplete course of vaccination. Reporter did not know lot number or route of administration of first also Reporter did not disclose vaccination facility details for first dose. The reporter consented to follow up.
Nausea, vomiting, diarrhea, difficulty swallowing water, weakness, fever. Symptoms lasted 10 days. Pt went to emergency room.
Slightly sore arm days 2&3 after vaccination, no visible reaction Red, hot, sore & itchy swath 3" X 6" one week after vaccination lasting 4 days so far.
Administration of an expired vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Administration of an expired vaccine) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (Administration of an expired vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Administration of an expired vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was provided.  No treatment information was provided.
The following information was received from a healthcare professional via distributor on 02 Apr 2015. A 27 year old female received IXIARO (batch number JEV13G42E) on 30 Mar 2015 i.m. On 02 Apr 2015 she had a positive pregnancy test. No adverse drug reaction reported.
Began with pain immediately when he got the vaccination.  Had redness develop about 12 hours later.
Received 3rd Hep B on 4/25/01. Noticed chills no fever for 1-2 wks. Rash, hives, joint pain, swelling in hands and legs. Rash is still present. Cortisone gives temporary relief. Cefntee ? 10mgm times 1 week gave a little relief. Advil taken for pain. Still c/o pain in legs. Also c/o pin pricking sensation in arms and legs.
Fever, headache, fatigue, nausea,  chills all lasted 36 to 48 hours.  Fatigue still after 48 hrs.
pt recvd vax 13JAN96 1130AM that evening rt arm was hurting & swollen;couldn't sleep on that side;pt was awaken during the noc w/cramps on lt lower leg, very painful;14JAN96 had pain (cramps) in both legs, lt one worse;loss of appetite;weak
PATIENT CALLED ME TODAY ON 09/010/2020 SAYING THAT SHE DEVELOPED SWELLING  AROUND INJECTION SITE ON RIGHT ARM , TENDER PAINFUL AS WELL  I ADVISED PATIENT TO TAKE TYLENOL AND APPLY COLD COMPRESSES AND CALL ME BACK TOMORROW  IF SYMPTOMS LASTS
In the early morning of 2/16, one week after receiving the vaccine, I woke up with nausea.  It was mild-moderate and I did not vomit, nor did I have a fever. Later that morning, I noticed a large, red patch of skin on my right arm, round the injection site.  It was itchy, and warm to the touch, but not painful. I called my doctor's office and reported it. I took photos and sent them to the doctor, and scheduled a telehealth appointment. Based on my symptoms and the photos, Dr recommended monitoring the site, my symptoms, and checking my temp once a day before prescribing any medication.  Today (2/20/21), the redness has improved, but is still visible. My temp is normal.
Gave 2nd dose of MMRV at 5 yr WCC.  Was given with Dtap-IPV.   Patient had already received MMRV  on 6/6/2019 and received MMR on 05/19/2016 and Varicella on 05/19/2016.  Parent is aware.    Spoke with Mom today and she states that patient is currently running low fever and is c/o nausea and stomach cramps.
This spontaneous report as received from a licensed practical nurse refers to a patient of unknown age and unknown gender. The patient pertinent medical history was not reported. On 29-APR-2014, the patient was vaccinated with PROQUAD (dose strength and route was not reported) (lot # J002306 and expiry date: 22-AUG-2014) which was improperly stored. Primary reporter was reporting excursion of 6 F since 01-JUN-2013 (confirmed date) affecting PROQUAD, nurse also reported that products were not stored in an overall average support range of -58 degree F and 5 degree F. No adverse effects reported. No product quality complaint (PQC) was reported for PROQUAD. This is one of several reports from the same reporter. Additional information has been requested.
Patient fainted - he slumped to his left side, leaning on his companion.  He was lethargic for about 3 minutes, sweaty and hot.
After well-baby check-up and vaccination on 4-20-09, visited physician on 4-23-09 with N/V and lethargy.  By that evening, she was taken to the ED with seizures.  At Hospital she was still having seizures and now decerebrate posturing.  At that time she was entubated.  On 4-25-09 she was transferred to Hospital where she was diagnosed with rt ICA dissecting aneurysm, s/p hemorrhage, cerebral ischemia/infarct, intracranial hypertension, seizures, lt hemiparesis, rt cranial nerve palsy, s/p decompression craniectomy, anemia and hyponatremia. On 6-4-09 she was transferred for rehabilitation after 41 days hospitalization.  6/19/09 Hospital records DC summary received DOS 4/29/09 to 6/4/09. Assessment: Cerebral infarction, ruptured intracranial hemorrhage, aneurysm of the right internal carotid artery. Patient presented with repeated episodes of vomiting. Appeared tired and sleepy. Later difficulty falling asleep, intermittent extending and flexing of right arm, kicking while asleep. Generalized jerking. Found unresponsive with unequal pupils. Respiratory failure - placed on ventilator. Bruise right thigh. Anemia. Endotracheal tube, gastric tube placed. Decompression craniotomy. Left lung collapse, right lung hyperinflated. Subsequent left hemiparesis, dysphagia, language delay.  7/29/09- ICD-9 codes: 430. 345.90, 518.81, 348.5, 787.29, 599.0, 348.2, 464.10, 0411.0, 342.90, 720.29.
Shingles left L1 dermatome developed evening of COVID 19 second dose vaccine. Patient is currently breastfeeding.
11 days post vax, pt broke out in about 100 tiny, little, red spots all over torso, without itching. Spots were not raised. Pt felt warm.
Difficulty breathing, shortness of breath. Continued cough and difficulty talking could not catch breath. Used prescribed inhaler, outcome was effective.
Injection site pain, tiredness, headache, muscle pain up and down Rt side of  body from neck to feet, itchy rash all over torso, heart palpitations and pain.
Body-widerash & itching. Temp 36.8 Celsius. Pulse 58. Respirations 16. BP 124/78. Seen in ER. Treatment in ER: SOLU MEDROL 125 ml IM, BENADRYL 25-50 ml q 6 hrs, PEPCID 20ml 2qd.
1st dose of SHINGRIX 2 years ago/ 2nd one on July 13th, 2021.; This case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a adult male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received on an unknown date, 2 years ago from the date of reporting).   On 13th July 2021, the patient received the 2nd dose of Shingrix. On 13th July 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. On an unknown date, the outcome of the drug dose administration interval too long was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The pharmacist reported that, patient (around 50-60 years old ) received the 1st dose of Shingrix 2 years ago, and the 2nd one later than the recommended interval, which led to lengthening of vaccination schedule. No further details were provided at the time of the call since the pharmacist was not in the office. The reporter consented to follow up.
Severe illness after the shot was administered about 12 hours later.  High fever that could not be controlled by Advil or Tylenol, registering at 103.0.  Vomiting 3 - 4 times. Never have felt this sick.  Blackout for a period of time. Suffered what is appearing to be a concussion since 10/21/21. Still seeing Neurologists, Pediatricians, Concussion Clinics, and ER Visit for CT Scan. Has since gone from high performing student not unable to complete an school day without a migraine. Is not being treated for convergence of the eyes as well. S
Child received DTP on 8/5/02 and on 8/6/02, mom says left arm where this immunization was given is red and swollen from shoulder all the was down to elbow which started around 17:00. Mom brought child to clinic at 08:00 on 8/7/02. Arm is swollen and red from shoulder down to elbow and complains of itching.
I received a call 4/7/16 at about 5pm from patient's wife that he was in a hospital in ICU, he was suffering from Guillain Barre Syndrome brought on by his flu shot--this is per his doctors. I do not know when problem started.
This vaccine combination was given 2 months too late. She had no indication for receiving Hib vaccine after 5 years of age and she was 5 years and 2 months at the time of injection. This was the incorrect choice of vaccine for the patient.
I95.9 HYPOTENSION 4/5/2023 ATRIAL FIBRILLATION, PAROXYSMAL
-14-21 around 4pm, noticed hard, hot, itching, redness, swelling, to injection site. Took benadrly orally and topically. lasted 2 days
Off and on since Thursday, a feeling of ?clogging? in ears, accompanied by muffled noise, as though water in ear. Seems worse after sleep. Also some fatigue.
Fever occurred the night of the vaccine, the following day he did not have a fever but had an episode of tightening of extremities and shaking movements while at the store. He was taken by ambulance to the ER. He did not need any medical intervention while in the ER and was discharged home after observation.
seizure; This spontaneous case was reported by a consumer and describes the occurrence of SEIZURE (seizure) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SEIZURE (seizure) (seriousness criterion medically significant). At the time of the report, SEIZURE (seizure) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were provided. Treatment for the events were not provided. Company comment: Very limited information regarding this event has been provided at this time. Further information has been requested; Sender's Comments: Very limited information regarding this event has been provided at this time. Further information has been requested
I had been getting hoarse off and on right after the shot then I would cough and it would hurt in my throat, and then on 10/15 I just got really hoarse and just cough really bad. So when it got to where you really could not hear me and the coughing would not stop and then my nose start running so on 10/18 I went to se dr.
My son had a reaction to the shot after he got his bath last night. He started complaining that his back was on fire. I checked him and found that his back was extremely hot. There was no redness or rash. Gave him Motrin. Got up this morning and was still having problems. He put aloe on his back and it seemed to cool him down. Called pharmacist and she said that she had never heard any one complain about this symptom.
1st shingles shot, it didn't have much affect; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   The patient's past medical history included shingles (had shingles 6 times).   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced shingles. The patient was treated with acyclovir (Zovirax) and valaciclovir hydrochloride (Valtrex). On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 8-APR-2022 Reporter's Comment: The patient self-reported this case via interactive digital media. The patient had shingles 6 times, pain pills the only relief. The patient received dose of Shingles vaccine but it didn't have much affect but he/she kept a prescription of Zoverex or Valtrex on hand all the time. The patient stated that the shingle virus must be treated by one of these two (Zoverex or Valtrex) within the first 3 to 4 days or it could affect your nerve roots. The patient also stated that the shingles medical name was Herpes Zoster. Additional supportive information: The follow-up would not possible, as no contact details were available.
completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose:1/27/2021.pfizer Lot#EL9262 2nd dose:01/06/21.pfizerLot#EL9262 Diagnosed covid positive: 03/24/21 Exposure:Unknown Symptoms:Headache, rhinorrhea, Insomnia, loss of smell, congestion
Significant swelling, redness, burning for 5 days. Today, 21 days later, there is still redness, heat, and bruising. Fatigue has been present since day one as well.
Inj. site became hard and itchy after 48 hours difficult to move arm in 72 hours. Patient treated with ibuprofen and warm compress. Much improved after 4 days.
Patient was given 0.5mL of the Moderna Bivalent covid vaccines instead of 0.5mL of the Moderna Covid vaccine (primary series)
Possible UTI ( Test was Negative); Rash on the injection site; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 24-Mar-2021 and was forwarded to Moderna on 24-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of URINARY TRACT INFECTION (Possible UTI ( Test was Negative)) and INJECTION SITE RASH (Rash on the injection site) in a 91-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 27-Feb-2021, the patient experienced INJECTION SITE RASH (Rash on the injection site). On 20-Mar-2021, the patient experienced URINARY TRACT INFECTION (Possible UTI ( Test was Negative)). At the time of the report, URINARY TRACT INFECTION (Possible UTI ( Test was Negative)) and INJECTION SITE RASH (Rash on the injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information were Keflex Antibiotics .
Nerve pain left side of face/left eye, left occipital pain, pain C-1-2. Shot given deltoid right under left shoulder bone.
Information has been received from a nurse referring to an unspecified number of patients of unknown age and gender. The patients' medical history, concomitant therapy and drug reactions were not reported. On unspecified dates, the patients were each vaccinated with a dose of improperly stored of PEDVAXHIB (lot #, expiration date, dose and route were not provided) for prophylaxis, which were exposed to 28.8 Fahrenheit (F) for 8 hours 43 minutes. There was no previous temperature excursion. No adverse effects were reported. The data logger issue was involved. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1612USA000631: US-009507513-1612USA009008.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 25-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 11-Jan-2021 at 9:48 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 11-Jan-2021, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). In 2021, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was reported as 25.13 administered on 11-Jan-2021.  Concomitant products were not provided.  On 11-Jan-2021, Excursion time was 02 PM, temperature was 35, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 08-Jan-2021, vial was moved to clinic on 11-Jan-2021. 09 vials were sent to clinic. Vaccine BUD date was 07-Feb-2021.   The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported.
When I woke up the day after using the vaccine on 5/21/2021  my lips were swollen and my feet have had a feeling of pins and needles since then.  It is a little painful but its more uncomfortable and it's impossible for me to keep my feet warm. My feet feel better when I'm not walking on them.